<DOC>
	<DOCNO>NCT02244632</DOCNO>
	<brief_summary>The purpose characterise tolerability Modufolin combination 5-FU alone , combination 5-FU Oxaliplatin , combination 5-FU Irinotecan combination 5-FU , Oxaliplatin Bevacizumab . Another purpose investigate 4 dos Modufolin identify best dose assessment .</brief_summary>
	<brief_title>ModufolinÂ® Combination With 5-Fluorouracil Alone Together With Oxaliplatin Irinotecan Colorectal Cancer</brief_title>
	<detailed_description>The study investigate tolerability Modufolin four ( 4 ) dose level ( 30 , 60 , 120 240 mg/m2 ) two ( 2 ) treatment combination chemotherapeutic agent 5-FU Oxaliplatin eight ( 8 ) week treatment . The tolerability two ( 2 ) low dos Modufolin ( 30 60 mg/m2 ) also investigate one treatment combination chemotherapeutic agent Irinotecan . The tolerability Modufolin dose assess favourable profile investigate treatment combination 5-FU , Oxaliplatin Bevacizumab eight ( 8 ) week treatment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Tetrahydrofolates</mesh_term>
	<criteria>Advanced metastatic colorectal ( Stage IV ) cancer verify biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Colorectal carcinoma</keyword>
	<keyword>Colorectal tumor</keyword>
	<keyword>Intestinal Neoplasm</keyword>
	<keyword>Gastrointestinal Neoplasm</keyword>
	<keyword>Gastrointestinal disease</keyword>
	<keyword>5,10-methylenetetrahydrofolate</keyword>
	<keyword>Tetrahydrofolates</keyword>
	<keyword>Therapeutic us</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Safety assessment</keyword>
</DOC>